What's Trending in Stocks Right Now
Discover which stock market news stories are capturing the most attention today. This page shows you the most-viewed articles on StockTitan, updated every minute based on real visitor traffic. See what tens of thousands of traders and investors are reading right now.
Why this matters: When a news story suddenly gets massive readership, it often indicates significant market interest in that stock or sector. By tracking the most popular articles, you can quickly identify which companies and events are drawing investor attention and potentially moving markets.
This isn't editorial content or sponsored placement—it's based purely on reader activity. Every story below earned its position through actual page views from real visitors, making this an authentic snapshot of what the trading community finds most interesting. Whether it's earnings reports, FDA decisions, merger news, or market analysis, the most-read stories rise to the top.
Updated Every Minute: Market sentiment shifts quickly. This ranking is recalculated every 60 seconds to reflect the latest reading trends. What's trending now could be completely different in an hour as new stories break and capture attention.
Progress Software (Nasdaq: PRGS) has agreed to acquire substantially all assets and assume certain liabilities of Domo’s AI and data products platform for a cash purchase price of $400 million, in an asset purchase transaction.
According to Progress Software, the deal is expected to expand its AI-focused data platform with Domo’s agentic, cloud-native analytics capabilities, adding more than 2,400 business customers and a broad ecosystem of cloud data warehouse partners. The transaction is expected to close within Progress’ fiscal year ending November 30, 2026, subject to regulatory approvals and customary conditions, and will be funded with a combination of cash and the company’s existing revolving credit facility. Progress reiterated that its fiscal Q3 revenue and non-GAAP EPS are anticipated to be within or above the high end of guidance issued on June 30, 2026.
- $400 million asset purchase to expand AI and data platform
- Acquisition adds over 2,400 Domo business customers
- Expected closing within fiscal year ending November 30, 2026
- Deal funded with cash and existing revolving credit facility
- Q3 revenue and non-GAAP EPS guided within/above prior high end
- None.
AtlasClear Holdings (NYSE American: ATCH) signed a non-binding letter of intent to acquire a revenue-generating institutional digital asset business and amended its letter of intent to acquire Ark Financial Services and its subsidiary Dawson James Securities. The Target’s identity will be disclosed upon signing a definitive agreement.
According to AtlasClear, based on 2025 results the Target generated about $9.2 million revenue and $3.5 million EBITDA, while Dawson James generated about $26.2 million revenue and just over $3.2 million EBITDA, implying a combined addition of roughly $35.4 million revenue and $6.7 million EBITDA. Unaudited data through June 2026 indicate a combined 2026 revenue run rate of over $56 million. The Target would be purchased for cash and AtlasClear stock, subject to definitive agreements, due diligence and required regulatory and stockholder approvals.
The Dawson James term sheet amendment allows an initial closing of 24.9% of Ark Financial within about 30 days without FINRA approval, with full ownership contingent on FINRA and AtlasClear shareholder approvals. AtlasClear has temporarily withdrawn applications to acquire Commercial Bancorp of Wyoming and plans to refile with an expanded business plan including digital assets.
- 2025 combined revenue + EBITDA contribution: about $35.4M revenue and $6.7M EBITDA from the Target and Dawson James
- 2026 revenue run rate: unaudited combined run rate over $56M through June 2026
- Digital asset expansion: entry into institutional digital asset markets via a revenue-generating, multi-jurisdictionally registered platform
- Dawson James initial 24.9% stake targeted to close within ~30 days, expanding capital markets capabilities
- Dawson James clearing through Wilson-Davis enables AtlasClear to capture economics from capital raising through clearing and settlement
- Digital asset acquisition LOI non-binding and subject to definitive agreement, due diligence and multiple approvals
- Full Dawson James ownership contingent on FINRA and AtlasClear shareholder approvals, creating timing and completion uncertainty
- Commercial Bancorp acquisition applications withdrawn and to be refiled later, potentially delaying banking integration
Hyliion (NYSE American: HYLN) announced it has been awarded a $41.7 million cost-plus-fixed-fee contract by the U.S. Navy’s Office of Naval Research. The contract covers design, development, construction, testing and delivery of 2 MW and 3 MW KARNO power generation systems at Navy-identified locations.
- $41.7 million cost-plus-fixed-fee contract from U.S. Navy Office of Naval Research
- Contract funds design and delivery of 2 MW and 3 MW KARNO systems
- Award validates KARNO megawatt-scale power generation technology with a U.S. defense customer
- None.
IBM (NYSE: IBM) reported second-quarter 2026 revenue of $17.2 billion, up 1% year over year, with GAAP net income from continuing operations of $2.2 billion and diluted EPS of $2.27. Gross margin was 57.7%, down 1.0 point, and pre-tax income margin was 14.4%.
Software revenue rose 5% to $7.8 billion, driven by Hybrid Cloud (Red Hat) +11% and Data +19%. Consulting was flat at $5.3 billion, while Infrastructure declined 7% to $3.8 billion, including a 42% drop in IBM Z and a 37% increase in Distributed Infrastructure. Financing revenue grew 12%.
IBM generated Q2 operating cash flow of $2.6 billion (up $0.9 billion) and free cash flow of $2.5 billion (down $0.3 billion). For the first half, free cash flow was $4.8 billion, flat year over year. IBM invested $10.5 billion in acquisitions year to date and ended the quarter with $8.2 billion in cash, restricted cash and marketable securities and total debt of $62.0 billion.
According to IBM, full-year 2026 constant-currency revenue growth is now expected at 4–5%, with currency neutral to growth, and free cash flow is expected to increase by about $1 billion year over year. The board declared a quarterly dividend of $1.69 per share, payable September 10, 2026, to shareholders of record on August 10, 2026.
- Total revenue $17.2B, up 1% year over year in Q2 2026
- Software segment revenue $7.8B, up 5% year over year
- Data subsegment revenue up 19% year over year
- Hybrid Cloud (Red Hat) revenue up 11% year over year
- Distributed Infrastructure revenue up 37% year over year
- Financing revenue $0.2B, up 12% year over year
- Operating (non-GAAP) pre-tax income $3.3B, up 3% year over year
- Operating (non-GAAP) diluted EPS $2.93, up 5% year over year
- Q2 operating cash flow $2.6B, up $0.9B year over year
- First-half 2026 operating cash flow $7.8B, up $1.7B year over year
- Full-year 2026 constant-currency revenue growth guided to 4–5%
- Full-year 2026 free cash flow expected to rise about $1B year over year
- Order backlog in Distributed Infrastructure nearly $500M
- Acquisitions year to date $10.5B invested
- Quarterly dividend $1.69 per share approved
- GAAP net income from continuing operations down 1% year over year
- GAAP diluted EPS $2.27, down 2% year over year
- Gross margin 57.7%, down 1.0 percentage point year over year
- GAAP pre-tax income $2.5B, down 5% year over year
- GAAP pre-tax margin 14.4%, down 0.9 percentage point year over year
- Infrastructure segment revenue $3.8B, down 7% year over year
- IBM Z revenue down 42% year over year
- Transaction Processing software revenue down 8% year over year
- Q2 free cash flow $2.5B, down $0.3B year over year
- Cash, restricted cash and marketable securities $8.2B, down $6.3B from year-end 2025
- Total debt $62.0B, up $0.7B year to date
- Revenue headwinds reported late in the quarter
Domo (NASDAQ: DOMO) announced a definitive agreement for Progress Software (NASDAQ: PRGS) to acquire substantially all of Domo’s assets, employees and certain liabilities, including its operating business and AI/data platform, for $400 million in cash, subject to customary purchase price adjustments.
At closing, Domo expects to have approximately $246 million of net cash, or $4.84 per share, an 81% premium to its 30‑day volume‑weighted average price, and to retain more than $900 million of net operating loss carryforwards. The existing credit facility will be repaid in full. Domo will remain a publicly listed Delaware holding company, under a new name and ticker, with a debt‑free balance sheet, limited operating expenses and certain retained assets. Its Board plans to seek transactions to monetize the NOLs and may consider returning capital to shareholders. Founder and CEO Josh James and the current Board will continue to lead the company. The deal, unanimously approved by Domo’s Board and supported by an irrevocable consent from the controlling shareholder, is expected to close by November 30, 2026, subject to regulatory approvals and customary conditions, and is not subject to a financing condition.
- $400 million all-cash sale of substantially all operating assets
- Expected $246 million net cash at closing, or $4.84 per share
- Implied 81% premium to 30-day volume-weighted average share price
- Retention of more than $900 million in net operating loss carryforwards
- Existing credit facility to be fully repaid at transaction closing
- Post-closing debt-free public entity with limited operating expenses
- Sale removes Domo’s operating business, leaving a holding company with limited operations
- Future value depends on Board’s ability to monetize $900+ million of NOLs
- Transaction closing subject to required regulatory approvals and customary conditions
Tesla (NASDAQ: TSLA) reported Q2 2026 revenue of $28.24 billion, up 26% year over year, driven by record quarterly vehicle deliveries and strong Services and Other growth. GAAP operating income fell 57% to $398 million, compressing operating margin to 1.4% from 4.1%.
GAAP net income attributable to common stockholders declined 5% to $1.11 billion ($0.32 diluted EPS), with a large contribution from interest and other income, including a SpaceX equity gain. Non-GAAP net income was $1.15 billion ($0.33 diluted EPS). Operating cash flow rose 85% to $4.70 billion, but capital expenditures surged 142% to $5.79 billion, resulting in negative free cash flow of $1.09 billion. Cash and investments reached $43.52 billion. Automotive revenue grew 23% to $20.52 billion, energy revenue 13% to $3.14 billion, and Services and Other 50% to $4.58 billion. According to Tesla, Q2 marked its first time exceeding $100 billion in trailing twelve‑month revenue.
- Total revenue up 26% YoY to $28.24 billion
- Operating cash flow up 85% YoY to $4.70 billion
- Cash, equivalents and short-term investments up 18% YoY to $43.52 billion
- Vehicle deliveries up 25% YoY to 480,126 units
- Energy storage deployments up 41% YoY to 13.5 GWh
- Active FSD subscriptions up 56% YoY to 1.48 million
- GAAP operating income down 57% YoY to $398 million; 1.4% margin
- Free cash flow swung to -$1.09 billion from $146 million YoY
- Automotive regulatory credit revenue down 67% YoY to $146 million
- Energy segment gross margin down to 20.4% from 30.3%
- Non-GAAP diluted EPS down 18% YoY to $0.33
- Operating expenses up 47% YoY to $4.35 billion
The Vita Coco Company (NASDAQ: COCO) has acquired Copra, a leading producer of super-premium Thai Nam Hom coconut water, in a transaction that closed on July 22, 2026. The deal gives Vita Coco immediate entry into the fast-growing, chilled super-premium coconut water segment, where it previously did not compete.
The upfront purchase price is $175 million, paid 80% in cash on hand and 20% in Vita Coco common stock, subject to customary adjustments. An additional earnout in 2029, based on 2028 performance, ranges from a $45 million floor to a $100 million cap. Copra, which operates a factory in Thailand with access to Nam Hom coconuts, has delivered a 48% Net Sales CAGR over the past three years and expects 2026 Net Sales above $100 million. According to Vita Coco, Copra’s sales are predominantly in the Americas, with international expansion and branded growth potential, and the acquisition is expected to be accretive to Vita Coco’s Adjusted EBITDA margins after full integration.
- $175 million upfront acquisition of Copra completed July 22, 2026
- Copra Net Sales CAGR 48% over past three years
- Copra expects 2026 Net Sales > $100 million
- Earnout tied to 2028 results capped at $100 million
- Funding structure uses 80% cash on hand, limiting new financing needs
- Vita Coco expects acquisition to be accretive to Adjusted EBITDA margins
- Upfront consideration of $175 million plus earnout up to $100 million
- 20% of initial purchase price paid in stock, implying shareholder dilution
QuantumScape (NASDAQ: QS) announced that its second quarter 2026 business and financial results, for the period ended June 30, are available in a shareholder letter on its Investor Relations website.
The company will host a live webcast on July 22, 2026 at 2 p.m. Pacific Time (5 p.m. Eastern), featuring CEO Siva Sivaram and CFO Kevin Hettrich, with a replay archived for 12 months.
- None.
- None.
Pfizer (NYSE:PFE) reported that the U.S. FDA has accepted for Priority Review a supplemental New Drug Application for TALZENNA (talazoparib) plus XTANDI (enzalutamide) to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer (mCSPC). The FDA set a PDUFA action date in the last quarter of 2026. The regimen is already approved in the U.S. for HRR gene‑mutated metastatic castration‑resistant prostate cancer (mCRPC); approval of this filing would move use into an earlier disease setting.
The application is supported by Phase 3 TALAPRO‑3 data in 599 patients, where TALZENNA plus XTANDI reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI, showing consistent benefit across BRCA and non‑BRCA HRR alterations and no new safety signals. TALZENNA plus XTANDI for HRR‑mutated mCSPC is also under review by the European Medicines Agency. The release additionally outlines detailed safety information, including risks of myelodysplastic syndrome/acute myeloid leukemia, significant myelosuppression rates, embryo‑fetal toxicity, and important drug‑interaction and dosing guidance, particularly in renal impairment.
- FDA Priority Review granted for TALZENNA + XTANDI sNDA in HRR-mutated mCSPC with PDUFA in late 2026
- 52% reduction in risk of radiographic progression or death in Phase 3 TALAPRO-3 versus placebo + XTANDI
- TALZENNA + XTANDI already approved for mCRPC in more than 60 countries
- XTANDI approved in one or more indications in 80+ countries, with 1.5 million patients treated globally
- MDS/AML reported in 0.4% of TALZENNA-treated solid tumor patients; similar rate in TALAPRO-2 combination arm
- Grade ≥3 anemia in 48%, neutropenia in 19%, thrombocytopenia in 9% of patients on TALZENNA + enzalutamide
- Red blood cell transfusions required in 42% of TALZENNA + enzalutamide patients in TALAPRO-2
- XTANDI associated with seizures in up to 2.2% of patients with predisposing factors and increased fracture/fall risk